Elanco
ELAN
$26.18
+13.88%
Elanco Animal Health is a global animal health company that develops, manufactures, and markets pharmaceutical products for both companion animals (pets) and food animals (cattle, swine, poultry, etc.). It is a major pure-play animal health company, having been spun off from Eli Lilly and subsequently grown through significant acquisitions like Bayer Animal Health, which positioned it as a top-tier competitor in the industry. The current investor narrative revolves around its ongoing integration of past acquisitions and its path toward sustainable profitability, with recent attention focused on its quarterly earnings volatility, debt reduction efforts, and the performance of its Pet Health segment versus its traditional Farm Animal business.…
ELAN
Elanco
$26.18
Related headlines
Investment Opinion: Should I buy ELAN Today?
Rating: Hold. The core thesis is that Elanco is a high-risk, high-reward turnaround story where the anticipated earnings recovery is already significantly priced in, but operational execution remains too volatile to justify a Buy rating at current levels.
Supporting this Hold view are several key data points: 1) The forward P/E of 19.29x is reasonable for a company expected to return to growth, but it offers limited margin of safety. 2) While revenue grew 12.16% YoY in Q4, sequential declines highlight instability. 3) Profitability metrics are deeply negative (trailing net margin -4.92%), but free cash flow of $284M provides a financial cushion. 4) Analyst sentiment is cautiously optimistic with an upgrade recently, but only 5 analysts cover the stock, indicating limited consensus conviction.
The two biggest risks invalidating a neutral stance are: 1) A failure to achieve the forward EPS of $1.52, which would cause the forward P/E multiple to expand unsustainably or collapse. 2) A continuation of gross margin volatility below 40%. This Hold would upgrade to a Buy if the stock corrects to the $18-$20 range (offering a better risk/reward) and the company demonstrates two consecutive quarters of stable, expanding operating margins above 5%. It would downgrade to Sell if quarterly net losses persist or revenue growth turns negative. Relative to its own volatile history and given the execution risk, the stock is fairly valued, not undervalued.
Sign up to view all
ELAN 12-Month Price Forecast
The outlook for ELAN is bifurcated between its promising forward earnings trajectory and its demonstrably volatile recent operational performance. The base case (50% probability) of choppy progress toward targets is most likely, suggesting limited near-term upside from current levels. The high beta and short interest make the stock a leveraged bet on quarterly execution. The stance would upgrade to Bullish on clear evidence of sustained margin improvement (e.g., two quarters of gross margin >45%) and a pullback to the low $20s. It would turn Bearish if the company posts another significant quarterly net loss, confirming the turnaround has stalled.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elanco's 12-month outlook, with a consensus price target around $34.03 and implied upside of +30.0% versus the current price.
Average Target
$34.03
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$21 - $34
Analyst target range
Analyst coverage for ELAN is limited, with only 5 analysts providing estimates, indicating it is a mid-cap stock with moderate institutional following. The consensus leans bullish, as evidenced by recent institutional ratings which include several 'Overweight' or 'Buy' recommendations from firms like Keybanc, Leerink Partners, and JP Morgan, alongside 'Equal Weight' from Morgan Stanley. A notable upgrade occurred in January 2026 when Piper Sandler moved from 'Neutral' to 'Overweight'. The average revenue estimate for the forward period is $6.0 billion, with a tight range between $5.93 billion and $6.04 billion, suggesting high conviction on the top-line outlook. The average EPS estimate is $1.525. Without a specific consensus price target provided in the data, the implied upside or downside cannot be calculated, but the recent ratings activity and upgrade signal a generally positive analyst sentiment building around the company's forward earnings potential and strategic execution.
Bulls vs Bears: ELAN Investment Factors
The investment debate for Elanco centers on a powerful, evidence-based bull case for a sustained turnaround versus a bear case highlighting persistent operational fragility. The bulls have stronger near-term evidence in the form of a 137% price rally, positive analyst upgrades, and a forward-looking valuation that anticipates profitability. However, the bears point to incontrovertible evidence of severe quarterly earnings volatility, negative trailing profitability, and high operational risk. The single most important tension is the company's ability to translate its strong revenue base and free cash flow into consistent, predictable profitability. If Elanco can stabilize its gross margins above 45% and deliver on its forward EPS of $1.52, the bull thesis will be validated. If quarterly losses and margin compression persist, the bear case of a failed turnaround will dominate.
Bullish
- Strong 1-Year Price Recovery: The stock has surged 137.70% over the past year, significantly outperforming the S&P 500's 29.04% gain, indicating a powerful reversal in market sentiment. This rally has lifted the stock from its 52-week low of $9.42 to a recent high of $27.72, demonstrating strong investor confidence in the turnaround narrative.
- Positive Forward Earnings Outlook: Analysts project a return to profitability with a forward EPS of $1.525, translating to a forward P/E of 19.29x, a stark improvement from the negative trailing P/E of -48.42x. This forward multiple suggests the market is pricing in successful execution of the company's strategic plan and integration efforts.
- Robust Free Cash Flow Generation: The company generates substantial trailing twelve-month free cash flow of $284 million, providing crucial internal funding for debt reduction and strategic initiatives. This strong cash flow, coupled with a healthy current ratio of 2.17, indicates solid liquidity and financial flexibility.
- Analyst Sentiment Turning Bullish: Recent analyst activity includes an upgrade from Piper Sandler to 'Overweight' in January 2026, and firms like Keybanc and JP Morgan maintain 'Buy' or 'Overweight' ratings. This positive shift in sentiment is underpinned by a consensus forward revenue estimate of $6.0 billion, showing conviction in the top-line trajectory.
Bearish
- Severe Quarterly Profitability Volatility: The company posted a massive Q4 2025 net loss of $276 million, and gross margin collapsed to 39.34% from 53.39% in the prior quarter. This extreme volatility, with operating margins swinging from 10.1% in Q1 2025 to 1.66% in Q4, highlights deep operational instability and integration challenges.
- Negative Trailing Profitability Metrics: Trailing metrics are deeply negative: a net margin of -4.92%, a Return on Equity of -3.54%, and a trailing P/E of -48.42x. These figures confirm the company is currently destroying shareholder value and underscore the high execution risk in achieving projected forward earnings.
- High Volatility and Recent Underperformance: With a beta of 1.877, the stock is 88% more volatile than the market, amplifying downside risk. This is evident in its recent 3-month decline of -6.52%, starkly underperforming the S&P 500's +4.14% gain, signaling a loss of momentum and heightened investor skepticism.
- Revenue Concentration and Cyclical Exposure: Over 55% of revenue comes from the Farm Animal segment ($640M in Q4 2025), which is exposed to cyclical agricultural commodity prices and disease outbreaks. This concentration creates earnings vulnerability, as seen in the sequential revenue decline from $1.241B in Q2 to $1.144B in Q4.
ELAN Technical Analysis
The stock is in a sustained recovery trend over the past year, with a remarkable 1-year price change of +137.70%, but is currently experiencing a near-term pullback. As of the latest close at $22.51, the stock is trading at approximately 81% of its 52-week range (between $9.42 and $27.72), indicating it has retreated from recent highs but remains significantly elevated from its lows. This positioning suggests the stock is consolidating after a powerful rally, with the high relative strength versus the S&P 500 (1-year relative strength of +108.66) highlighting its outperformance. Recent momentum has turned negative, with the stock down 2.64% over the past month and down 6.52% over the past three months, diverging sharply from the strong yearly trend. This short-term weakness contrasts with the S&P 500's gains of 9.98% and 4.14% over the same periods, respectively, indicating ELAN is undergoing a significant correction and relative underperformance. The stock's high beta of 1.877 signals it is approximately 88% more volatile than the broader market, which amplifies both its recent gains and current pullback. Key technical support is at the 52-week low of $9.42, while immediate resistance is at the 52-week high of $27.72; a sustained move above $27.72 would signal a resumption of the primary uptrend, while a breakdown below recent lows near $21.80 could indicate a deeper correction is underway.
Beta
1.69
1.69x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$11-$28
Price range past year
Annual Return
+175.3%
Cumulative gain past year
| Period | ELAN Return | S&P 500 |
|---|---|---|
| 1m | +14.7% | +11.4% |
| 3m | +7.7% | +8.3% |
| 6m | +21.8% | +9.4% |
| 1y | +175.3% | +31.3% |
| ytd | +16.3% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELAN Fundamental Analysis
Revenue growth has been positive but uneven, with the most recent Q4 2025 revenue of $1.144 billion representing a 12.16% year-over-year increase. However, examining sequential quarters reveals volatility: revenue declined from $1.241 billion in Q2 2025 to $1.144 billion in Q4 2025. Segment data shows Farm Animal revenue ($640 million) is the largest contributor, followed by Pet Health ($489 million), indicating the company's dual revenue streams but also exposure to cyclical agricultural markets. Profitability remains a critical challenge, as evidenced by a net loss of $276 million in Q4 2025 and a trailing net margin of -4.92%. Gross margin compressed significantly to 39.34% in Q4 2025 from 53.39% in Q3 2025, highlighting severe quarterly volatility and potential cost pressures. The operating margin was a thin 1.66% in the latest quarter, though it has fluctuated between positive and negative figures in recent periods, underscoring the company's struggle to achieve consistent operational profitability. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.61, and a strong current ratio of 2.17 indicates good short-term liquidity. Trailing twelve-month free cash flow is a positive $284 million, providing internal funding capacity, but Return on Equity (ROE) is negative at -3.54%, reflecting inefficient use of shareholder equity amidst recent losses.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.12%
YoY Comparison
Gross Margin
+0.39%
Latest Quarter
Free Cash Flow
$284000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELAN Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Elanco trades at a trailing PS ratio of 2.38 and an Enterprise Value-to-Sales (EV/Sales) of 3.19. The forward PE ratio of 19.29x, based on estimated positive EPS, indicates the market is pricing in a return to profitability, creating a significant gap from the negative trailing PE of -48.42x. Compared to industry averages, data is not available in the provided dataset for a direct sector PS or EV/Sales comparison, limiting the peer analysis. However, the company's gross margin of 43.48% and operating margin of 5.34% provide a baseline for assessing whether its sales multiple is justified by underlying profitability. Historically, the stock's own PS ratio has fluctuated dramatically, from a low near 3.67 in early 2023 to a high of 13.74 in late 2021. The current PS of 2.38 is at the lower end of this multi-year range, suggesting the market is applying a discounted multiple relative to its own history, likely reflecting concerns over recent margin compression and earnings volatility.
PE
-48.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -240x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, stemming from extreme quarterly earnings volatility. The Q4 2025 net loss of $276 million and the gross margin collapse from 53.39% to 39.34% sequentially demonstrate severe cost control and integration issues. The company's negative trailing net margin of -4.92% and ROE of -3.54% confirm it is currently eroding shareholder capital. While free cash flow is positive at $284 million, the path to sustainable net income is fraught with execution risk, and the business remains heavily reliant on the cyclical Farm Animal segment for over half its revenue.
Market & Competitive Risks are elevated due to the stock's high volatility (beta 1.877) and recent underperformance. Trading at a forward P/E of 19.29x, the valuation is entirely dependent on achieving projected earnings; any stumble could trigger significant multiple compression. The stock's 1-year rally of 137% has likely front-loaded optimism, making it vulnerable to profit-taking and sector rotation away from speculative turnarounds. Furthermore, as a pure-play animal health company, it faces intense competition from larger, more diversified players like Zoetis, which could pressure pricing and market share.
Worst-Case Scenario involves a failure to achieve forecasted profitability, leading to a loss of analyst confidence and a re-rating back towards valuation levels seen during its distress. A specific chain could be: Q1 2026 earnings miss due to persistent margin pressure, triggering analyst downgrades and a sell-off exacerbated by the high short interest. The stock could then retrace a significant portion of its rally, testing the $15-$18 range. A realistic downside from the current $22.51 is approximately -35% to the $14-$15 level, which would represent a 50% retracement of the past year's gains and align with a re-test of prior technical support levels above the 52-week low of $9.42.
FAQ
The key risks are: 1) Execution Risk: The severe quarterly volatility in gross margin (from 53% to 39% in one quarter) and net income (Q4 loss of $276M) shows the business is unstable. 2) Cyclical & Concentration Risk: Over 55% of revenue comes from the Farm Animal segment, which is tied to agricultural commodity cycles. 3) Valuation Risk: The stock's 137% 1-year gain and forward P/E of 19.29x leave little room for error; an earnings miss could trigger a sharp decline. 4) Market Risk: With a beta of 1.877, ELAN will fall more than the market in a downturn. Execution risk is the most severe, as it directly threatens the core earnings recovery thesis.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $22 and $26, as the company makes uneven progress toward its $1.52 EPS target. The Bull Case (30% probability) could drive the stock to $28-$32 on successful execution and margin expansion. The Bear Case (20% probability) could see a decline to $14-$18 if operational challenges lead to an earnings miss and loss of analyst confidence. The base case is most likely, implying limited near-term upside from the current ~$22.50 price, with the key assumption being that the company can stabilize its profitability after a volatile Q4.
ELAN is fairly valued based on a forward-looking perspective, but richly valued on a trailing basis. The forward P/E of 19.29x is reasonable for a company expected to return to growth, but it is entirely contingent on achieving the estimated $1.52 EPS. On a trailing basis, the negative P/E of -48.42x and a Price-to-Sales ratio of 2.38 (at the low end of its own historical range) reflect past struggles. Compared to sector peers, direct data is unavailable, but the valuation implies the market is paying a fair price for anticipated future profits, not a discount for the current operational instability.
ELAN is a speculative buy, not a core holding. For risk-tolerant investors seeking a turnaround story, it offers potential upside if the company delivers on its forward EPS of $1.52. However, the investment carries significant risk, evidenced by a trailing net margin of -4.92%, extreme quarterly earnings volatility, and a high beta of 1.877. The stock has already rallied 137% in the past year, pricing in much of the optimism. It may be a good buy on a pullback below $20 for those with a high conviction in management's execution, but it is not suitable for conservative portfolios.
ELAN is primarily suitable for a medium- to long-term investment horizon of 2-3 years, contingent on the successful execution of its turnaround plan. The stock's high beta (1.877) and earnings volatility make it a poor candidate for short-term trading, as quarterly results can cause dramatic price swings. The lack of a dividend also removes any income incentive for long-term holders. Investors should be prepared to hold through potential volatility while monitoring the company's progress toward consistent profitability. A minimum holding period of 12-18 months is suggested to allow for several earnings cycles to validate or invalidate the recovery thesis.